Spiro bicyclic inhibitors of menin-MLL interaction

US12084462B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Patrick René Angibaud · Louviers, FR
• Vineet Pande · Vosselaar, BE
• Barbara Herkert · Flonheim, DE
• Daniel Jason Krosky · Blue Bell, US
• Olivier Alexis Georges Querolle · Évreux, FR
• Aaron Nathaniel Patrick · Doylestown, US
• Isabelle Noëlle Constance Pilatte · Louviers, FR

Key dates

• Filing date: Nov 29, 2021
• Grant date: Sep 10, 2024
• Expiry date: Jan 3, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.